A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
Phase 1
Completed
- Conditions
- Pulmonary FibrosisThyroid Eye Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Lassen Therapeutics 1 PTY LTD
- Target Recruit Count
- 75
- Registration Number
- NCT05331300
- Locations
- 🇦🇺
Site AU05, Hurstville, New South Wales, Australia
🇦🇺Site AU03, Brisbane, Queensland, Australia
🇦🇺Site AU01, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath